Small-molecule modulators of tumor immune microenvironment

Zhang, Jing; Yu, Jia; Liu, Meijing; Xie, Zhizhong; Lei, Xiaoyong; Yang, Xiaoyan; Huang, Sheng; Deng, Xiangping; Wang, Zhe; Tang, Guotao

doi:10.1016/j.bioorg.2024.107251

Cited by 3 publications

(1 citation statement)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After extensive clinical trials, several tumor immune microenvironment modulators have demonstrated therapeutic effects. For example, small-molecule PD-1/PD-L1 inhibitors (INCB086550 and IMMH-010), IDO1 inhibitors (LY-3381916 and Indoximod), and TGF-βRI inhibitors (LY-2157299, GW788388, EW-7197, and LY-3200882) can be used alone or in combination with immune checkpoint-targeting drugs to potentially achieve better efficacy [138][139][140][141]. Through a comprehensive analysis and precise modulation of the tumor immune microenvironment, we aim to develop a novel and effective immunotherapy pathway for elderly cancer patients.…”

Section: Immunosenescence and Cancermentioning

confidence: 99%

Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development

Feng,

He,

Liu

et al. 2024

IJMS

View full text Add to dashboard Cite

Cancer represents a significant threat to human health, and traditional chemotherapy or cytotoxic therapy is no longer the sole or preferred approach for managing malignant tumors. With advanced research into the immunogenicity of tumor cells and the growing elderly population, tumor immunotherapy has emerged as a prominent therapeutic option. Its significance in treating elderly cancer patients is increasingly recognized. In this study, we review the conceptual classifications and benefits of immunotherapy, and discuss recent developments in new drugs and clinical progress in cancer treatment through various immunotherapeutic modalities with different mechanisms. Additionally, we explore the impact of immunosenescence on the effectiveness of cancer immunotherapy and propose innovative and effective strategies to rejuvenate senescent T cells.

show abstract

Section: Immunosenescence and Cancermentioning

confidence: 99%

Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development

Feng,

He,

Liu

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Synthesis and immunotherapy efficacy of a PD-L1 small-molecule inhibitor combined with its 131I-iodide labelled isostructural compound

Lv,

Hu,

Zhang

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance

Wu,

Feng,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Adjuvant therapy is essential in cancer treatment to enhance primary treatment effectiveness, reduce adverse effects, and prevent recurrence. Small molecule inhibitors as adjuvants in cancer immunotherapy aim to harness their immunomodulatory properties to optimize treatment outcomes. By modulating the tumor microenvironment, enhancing immune cell function, and increasing tumor sensitivity to immunotherapy, small molecule inhibitors have the potential to improve patient responses. This review discusses the evolving use of small molecule inhibitors as adjuvants in cancer treatment, highlighting their role in enhancing the efficacy of immunotherapy and the opportunities for advancing cancer therapies in the future.

show abstract

Small-molecule modulators of tumor immune microenvironment

Cited by 3 publications

References 164 publications

Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development

Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development

Synthesis and immunotherapy efficacy of a PD-L1 small-molecule inhibitor combined with its 131I-iodide labelled isostructural compound

Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance

Contact Info

Product

Resources

About